Chemotherapy-related reactivation of hepatitis B infection: Updates in 2013

Hwi Young Kim, Won Kim

Hwi Young Kim, Won Kim, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul 156-707, South Korea

Author contributions: Kim HY collected data, reviewed literature, and wrote the manuscript; Kim W designed this review, appraised critically and revised the manuscript.

Correspondence to: Won Kim, MD, PhD, Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul 156-707, South Korea. drwon1@snu.ac.kr

Telephone: +82-2-8702233  Fax: +82-2-8312826

Received: October 29, 2013  Revised: February 18, 2014

Accepted: May 19, 2014

Published online: October 28, 2014

Abstract

Hepatitis B reactivation is a potentially serious complication of anticancer chemotherapy, which occurs during and after therapy. This condition affects primarily hepatitis B surface antigen (HBsAg)-positive patients, but sometimes HBsAg-negative patients can be at risk, based only on evidence of past infection or occult infection with a low titer of detectable hepatitis B virus (HBV) DNA. The clinical outcomes vary with the different degrees of virologic and biochemical rebound, ranging from asymptomatic elevations in liver enzymes to hepatic failure and even death. Despite the remarkable advancement in the treatment of chronic hepatitis B over the past decade, proper strategies for the prevention and management of HBV reactivation remain elusive. Moreover, with the increasing use of rituximab in patients with lymphoma, HBV reactivation in occult or past infections has become increasingly problematic, especially in HBV-endemic regions. This review addresses the current knowledge on the clinical aspects and management of chemotherapy-related HBV reactivation, updates from recent reports, several unresolved issues and future perspectives.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Hepatitis B virus; Chemotherapy; Reactivation

Core tip: Hepatitis B reactivation is a serious complication of anticancer chemotherapy, affecting both hepatitis B surface antigen-positive and anti-hepatitis B core antibody-positive patients. Although treatment of hepatitis B has been dramatically improved in the past decade, management of hepatitis B virus (HBV) reactivation remains unsatisfactory. This review covers updates from recent reports, unresolved issues and future perspectives on HBV reactivation.

Kim HY, Kim W. Chemotherapy-related reactivation of hepatitis B infection: Updates in 2013. World J Gastroenterol 2014; 20(40): 14581-14588 Available from: URL: http://www.wjgnet.com/1007-9327/full/v20/i40/14581.htm DOI: http://dx.doi.org/10.3748/wjg.v20.i40.14581

INTRODUCTION

Overview

Chronic infection with hepatitis B virus (HBV) is a major health burden that affects approximately 350 million people worldwide[1]. The hallmark of progressive liver disease in HBV infection is active viral replication. In contrast, patients with low serum HBV DNA level (usually below 1000 IU/mL) and normal alanine aminotransferase (ALT) activity are considered inactive carriers with a low risk of clinical progression. However, HBV reactivation can occur in these inactive carriers, either spontaneously or upon immunosuppression[2]. Impairment of the host immune system due to treatment with chemotherapeutic or immunosuppressive agents raises the risk of HBV re-
activation\(^{[3]}\). HBV reactivation presents with reemergence of necroinflammation in patients of inactive carrier status or even in patients with resolved hepatitis B\(^{[4]}\), which is preceded by rise in serum HBV DNA of 10 times or higher, sometimes reaching \(\geq 10^8\) IU/mL, with serum ALT elevation (\(\geq\) three times of upper limit of normal or an absolute rise of more than 100 IU/L)\(^{[5,6]}\). Prior to the diagnosis of HBV reactivation, it is necessary to exclude other conditions which might cause above-mentioned biochemical changes, including hepatic injury due to chemotherapy, metastatic malignancies in the liver, or hepatitis due to other viruses. The reported rate of HBV reactivation was diverse across literature, approximately ranging from 20%-50%. Although initial presentation of HBV reactivation is mostly asymptomatic, some patients show clinical deterioration with the development of jaundice or other signs of decompensation, with some patients dying due to hepatic failure\(^{[7,9]}\). Typically, serum HBV DNA becomes detectable during anticancer therapy or immunosuppression, and then serum ALT rises after completion of the treatment. If HBV reactivation occurs in relation to chemotherapy among patients with malignancy, subsequent treatment disruption or premature termination may adversely influence treatment outcomes\(^{[10-12]}\).

**Risk factors**
Several clinical predictors of HBV reactivation have been identified, including a certain serum HBV DNA level prior to immunosuppression, the type of underlying malignancy, the regimen of chemotherapy, and the intensity of immunosuppression. HBV reactivation occurs more frequently in patients with non-Hodgkin’s lymphoma with higher reported rates ranging from 24% to 67% compared to patients with solid tumors\(^{[8,13]}\). This finding is directly attributable to the intense chemotherapeutic regimens for lymphoma and relatively higher rates of hepatitis B surface antigen (HBsAg) positivity in lymphoma patients\(^{[8,13-15]}\). The risk of HBV reactivation is raised with corticosteroid use because of immune suppression or the direct stimulation of HBV replication. Rituximab, which commonly comprises chemotherapy regimens with corticosteroids for lymphoma, raises the risk of reactivation even further\(^{[16,17]}\). In hematopoietic stem cell transplantation for hematologic malignancies, preceding highly intensive chemotherapy frequently increases the risk of HBV reactivation\(^{[18,19]}\). Given the reactivation rate of 14%-21% in solid tumors, reactivation was more frequently reported in breast cancer (41%-56%), which might be explained by the higher doses of chemotherapy and the use of anthracycline\(^{[10,12,20]}\). Other known factors for the elevated risk of HBV reactivation are HBV genotype, specific mutations on HBV genome such as precore/core and precore promoter mutations, and recovery from neutropenia\(^{[22,28]}\). In addition to HBsAg-positive patients, HBV reactivation rarely occurs in anti-hepatitis B core immunoglobulin G (anti-HBe IgG)-positive patients without HBsAg; this result that can be interpreted as an occult HBV infection or a past infection\(^{[29]}\). In an occult or past HBV infection, HBV DNA can be detected in the hepatocytes or even in the serum with a low titer. If HBV reactivation occurs from the occult/past infection, HBV replication resumes following immunosuppression with or without the reemergence of HBsAg (reverse seroconversion or seroreversion of HBsAg)\(^{[27,28]}\). The risk of HBV reactivation in occult/past infection was particularly well documented in patients with rituximab-treated B-cell lymphoma or patients who underwent hematopoietic stem cell transplantation for their hematologic malignancies\(^{[29,30]}\). Low titer of hepatitis B surface antibody (HBsAb) was suggested as a risk factor of HBV reactivation in rituximab-treated lymphoma patients\(^{[31]}\). In addition, caution is needed in HBsAb-positive patients without HBsAg or anti-HBe IgG, since there have been case reports where HBV reactivation occurred in such patients causing fatality\(^{[32]}\). Risk factors for HBV reactivation are summarized in Table 1.

**Management**
In addition to its adverse influences on the maintenance of chemotherapy and on the outcomes of underlying malignancy, prevention of HBV reactivation is of paramount importance when considering the potential risk of hepatic failure or death. For prevention, the evidence of HBV infection (HBsAg and anti-HBe IgG) should be screened before the initiation of chemotherapy. HBV vaccination is indicated in case of negativity for both HBsAg and anti-HBe IgG. Preemptive antiviral therapy is needed for HBsAg-positive patients, irrespective of their serum HBV DNA levels\(^{[30]}\). Randomized controlled studies from Hong Kong and Taiwan demonstrated that preemptive lamivudine significantly reduced HBV reactivation, hepatic failure and mortality in lymphoma patients\(^{[14,19,37,38]}\). Based on those studies, current guidelines recommend starting preemptive antiviral therapy from the beginning of chemotherapy, rather than deferring until HBV DNA rises, and maintaining preemptive therapy for a specific period of time after the end of chemotherapy (e.g., 6 mo or longer, up to 12 mo)\(^{[38-40]}\). However, the optimal duration of preemptive antiviral therapy remains elusive to date due to the lack of evidence. The risk of HBV reactivation was increased after the cessation of preemptive lamivudine therapy 3 mo following the end of chemotherapy, particularly in cases with high pre-chemotherapy HBV DNA (\(\geq 2000\) IU/mL)\(^{[41]}\). Hence, the optimal duration for patients with high pretreatment HBV DNA can be determined according to the current treatment guidelines for chronic hepatitis B. In addition, it should be noted that HBV reactivation may occur following longer than 6 mo from the cessation of chemotherapy irrespective of the pretreatment viral load. Evidence on the proper choice of preemptive antiviral agents is also limited. However, antiviral agents other than lamivudine, such as adefovir, tenofovir, entecavir, and telbivudine, could be used for preemptive therapy, considering their similar mechanisms of action and advantages in potency.
High pre-chemotherapy viral load in patients who are negative for serum HBV DNA, including lymphoma receiving rituximab-based chemotherapy, however, may be determined based on periodic (e.g., monthly or bimonthly) monitoring of the serum HBV DNA in patients who are negative for serum HBV DNA prior to chemotherapy. Therefore, the preemptive use, other antiviral agents with a high genetic barrier to resistance should be preferred in cases of prolonged chemotherapeutic schedules (e.g., more than a year)[16]. Recently, a retrospective study demonstrated a reduced risk of hepatitis and chemotherapy disruption due to HBV reactivation with entecavir compared with lamivudine in lymphoma patients[17,29]. However, relevant data regarding the superior efficacy of entecavir and tenofovir for hepatitis B virus reactivation are limited, and resistance (especially for entecavir and tenofovir) is not clearly known, as previous reports showed that the absence or presence of low titers of anti-HBs was associated with the risk of HBV reactivation among lymphoma patients under rituximab-containing treatments[17,26,29]. Although the demonstration of decreasing anti-HBs titer was intriguing in the study by Pei et al[44] (n = 29) that reported that decreases in the anti-HBs titer after rituximab treatment occurred in 17 out of 150 lymphoma patients (11.3%), a meta-analysis by Dong et al[17,26,29] demonstrated HBV reactivation under rituximab-based chemotherapy in 17 out of 150 lymphoma patients with anti-HBc (HBsAg-negative), whilst HBV DNA was being monitored at baseline, at the start of every chemotherapy cycle, and every 4 wk after completion of chemotherapy[66]. In this study, hepatitis flare (defined as increase in ALT of 3 fold or higher, exceeding 100 IU/L) was more frequently associated with re-appearance of HBsAg after reactivation of HBV. Regarding the risk of reactivation of occult/past HBV infection in lymphoma patients, a meta-analysis by Dong et al[66], including 971 lymphoma patients from 9 studies, demonstrated that the relative risk of HBV reactivation by rituximab-based treatments was 5.52 (95%CI: 2.05-14.85, P = 0.0007) in patients with occult/past infections (anti-HBc IgG-positive, HBsAg-negative). Although the obvious heterogeneity in the included studies and presence of publication bias should be prudently taken into consideration when interpreting the results, this meta-analysis contributed further supporting evidence of the HBV reactivation risk in the lymphoma patient population with occult/past HBV infections. Another retrospective study from Japan included 109 HBsAg-negative patients (59 with anti-HBc undergoing chemotherapy for either lymphoma or multiple myeloma, in which serum HBV DNA was quantified monthly during and after chemotherapy in each study subject[67]. During the median follow-up period of 20.5 mo, four out of 59 anti-HBc-positive patients

| Categories | Risk factors | Ref. |
|------------|-------------|-----|
| Host factors | Male gender | [8] |
| Tumor- or treatment-related factors | Young age | [8] |
| | Elevated baseline ALT | [63] |
| | Lymphoma | [6,8] |
| | Hematologic malignancies | [8,64] |
| | Breast cancer | [6] |
| | Glucocorticoid use | [6,16] |
| | Anthracycline use | [6] |
| | Rituximab-based regimen | [17,29] |
| | Hematopoietic stem cell transplantation | [65] |
| Viral factors | High pre-chemotherapy viral load | [66] |
| | Positive HBsAg | [8,67] |
| | Presence of precore mutant | [25,68] |
| | Negative or low titer of HBsAb (in case of occult/past infection) | [17] |

ALT: Alanine aminotransferase; HBsAg: Hepatitis B e antigen; HBsAb: Hepatitis B surface antibody.

### LESSONS FROM RECENT REPORTS

Because the clinical practice guidelines for HBV infection, including the management of HBV reactivation, were released by AASLD (2009), EASL (2012) and APASL (2012)[14,40,43], this section mainly covers newer reports, released after these guidelines. During the past couple of years, research interests in the field of HBV reactivation have focused on lymphoma, particularly the risk of HBV reactivation with rituximab-based treatment in occult/past HBV infection. A retrospective study by Pei et al[44] (n = 29) reported that decreases in the anti-HBs titer after rituximab treatment were observed, especially in HBsAg-negative patients with low baseline anti-HBs titers (< 100 mIU/mL). This seems relevant, as previous reports showed that the absence or presence of low titers of anti-HBs was associated with the risk of HBV reactivation among lymphoma patients under rituximab-containing treatments[17,26,29]. Although the demonstration of decreasing anti-HBs titer was intriguing in the study by Pei et al[44], the small number of study subjects prevented the investigators from providing clearer and more robust evidence regarding the role of changing anti-HBs titers in the dynamic risk of HBV reactivation in rituximab-treated lymphoma patients. Indeed, hepatitis flares after chemotherapy occurred in only 6 patients. Instead, the study presented a provisional association of the risk of HBV reactivation with anti-HBs, in which the risk of hepatitis flares was higher in patients with lost anti-HBs after chemotherapy (4/8 vs 2/21, P = 0.033). A recent multi-center prospective study from Taiwan demonstrated HBV reactivation under rituximab-based chemotherapy occurred in 17 out of 150 lymphoma patients with anti-HBc (HBsAg-negative), whilst HBV DNA was being monitored at baseline, at the start of every chemotherapy cycle, and every 4 wk after completion of chemotherapy[66]. In this study, hepatitis flare (defined as increase in ALT of 3 fold or higher, exceeding 100 IU/L) was more frequently associated with re-appearance of HBsAg after reactivation of HBV. Regarding the risk of reactivation of occult/past HBV infection in lymphoma patients, a meta-analysis by Dong et al[66], including 971 lymphoma patients from 9 studies, demonstrated that the relative risk of HBV reactivation by rituximab-based treatments was 5.52 (95%CI: 2.05-14.85, P = 0.0007) in patients with occult/past infections (anti-HBc IgG-positive, HBsAg-negative). Although the obvious heterogeneity in the included studies and presence of publication bias should be prudently taken into consideration when interpreting the results, this meta-analysis contributed further supporting evidence of the HBV reactivation risk in the lymphoma patient population with occult/past HBV infections. Another retrospective study from Japan included 109 HBsAg-negative patients (59 with anti-HBc undergoing chemotherapy for either lymphoma or multiple myeloma, in which serum HBV DNA was quantified monthly during and after chemotherapy in each study subject[67]. During the median follow-up period of 20.5 mo, four out of 59 anti-HBc-positive patients...
developed HBV reactivation, and three of them were negative for anti-HBs. Due to the small sample size, the statistical significance of anti-HBe for HBV reactivation was not proven. However, the authors underscored that the HBV DNA should be monitored during and after chemotherapy in order to detect HBV reactivation earlier. In line with these reports, a cost-effectiveness analysis on HBV screening before chemotherapy for lymphoma was recently conducted in Canada[48]. Out of the three strategies (screening all patients, screening high-risk patients for HBV infections, and no screening), a decision tree model analysis revealed that the rate of HBV reactivation was reduced to one-tenth with screening all patients, resulting in lower costs among patients receiving rituximab-based chemotherapy for lymphoma. Prior to this report, another cost-effectiveness study on HBV screening from Australia was published[50]; its results indicated that universal HBV screening was not cost-effective in patients with solid tumors, specifically in hypothetical patient cohorts receiving adjuvant chemotherapy for early breast cancer or palliative chemotherapy for advanced non-small cell lung cancer. However, cost-effectiveness was maintained in limited HBsAg screening in the population with adjuvant chemotherapy. Taken together, cost-effectiveness seems to be dependent on the different risks of HBV reactivation in different clinical settings.

The proper choice of an antiviral agent is another important issue to be resolved. Lamivudine has been widely accepted as a representative antiviral agent for preemptive therapy in HBsAg-positive patients undergoing chemotherapy, based on the results of previous randomized controlled trials, as described earlier. However, the development of resistance to lamivudine has been a major concern in its preemptive use[50-52]. Newer potent antiviral agents with high genetic barriers to resistance have been launched in recent years, and their efficacy in the preemptive setting needs to be further investigated. A recent multinational retrospective study in Asia (n = 340) revealed that breakthrough HBV reactivation was observed in more than 20% of lamivudine-treated HBsAg-positive lymphoma patients undergoing rituximab-containing chemotherapy[56]. In this study, the entecavir-treated group showed a reduced rate of HBV reactivation compared with the lamivudine-treated group (6.3% vs 39.3%, P < 0.05). The optimal duration of preemptive antiviral therapy also remains unclear. In the rituximab era, late HBV reactivation has been reported up to 170 d after the last dose of rituximab-containing chemotherapy[57]. A recent retrospective study by Chen et al[54] reported that HBV reactivation occurred up to 230 d after the last dose of rituximab. It seems necessary to monitor the serum HBV DNA titers regularly during and after the completion of any rituximab-based chemotherapy in lymphoma patients as well as to consider longer durations of preemptive antiviral therapies, especially among those receiving prolonged chemotherapy. An intriguing case report from Italy showed that viral breakthrough occurred during entecavir prophylaxis in the absence of viral mutations in a patient with chronic lymphocytic leukemia under bendamustine therapy[56]. The authors argued that this uncontrolled viral replication resulted from “immunological escape” phenomenon under persistent and severe immune system impairment, necessitating combination treatment[56]. Although this combination strategy was advocated by a case report by the same author group[53], it requires further investigation.

Recently, a randomized controlled trial of prophylactic entecavir for lymphoma patients with resolved

---

**Table 2 Comparison of prophylactic strategies against the reactivation of hepatitis B with recent major guidelines**

| screening tests | AASLD (2009)[1] | EASL (2012)[40] | APASL (2012)[43] |
|----------------|----------------|----------------|-----------------|
| Duration of therapy | 6 mo after the completion of chemotherapy/immunosuppression, if baseline HBV DNA < 2000 IU/mL; continue treatment until treatment endpoints in immune competent patients if HBV DNA > 2000 IU/mL; Lamivudine or telbivudine if duration of treatment ≤ 12 mo and baseline HBV DNA is undetectable; tenofovir or entecavir if longer treatment duration is needed | 12 mo after cessation of chemotherapy | Lamivudine; anti-HBc in rituximab- or anti-TNF-α-treated patients |
| Antiviral agent | Lamivudine if low HBV DNA (< 2000 IU/mL) and a finite, short duration of immunosuppression is planned; entecavir or tenofovir if high HBV DNA and/or lengthy, repeated cycles of immunosuppression are planned | Monitor HBV DNA; treat when needed | Monitor HBV DNA; treat when needed |
| occult/ past infection | Monitor HBV DNA; treat if HBV DNA becomes detectable | Test for HBV DNA; if HBV DNA-positive, treat similarly to HBsAg-positive patients; if HBV DNA-negative, follow every 1-3 mo with ALT and HBV DNA and treat upon reactivation before ALT elevation; preemptive therapy can be given if monitoring is not guaranteed or in cases of stem cell transplantation |

AASLD: American Association for the Study of Liver Diseases; EASL: European Association for the Study of the Liver; APASL: Asian Pacific Association for the Study of the Liver; HBsAg: Hepatitis B surface antigen; anti-HBc: Anti-hepatitis B core antibody; TNF: Tumor necrosis factor; HBV: Hepatitis B virus; ALT: Alanine aminotransferase.
HBV infection was reported[61]. Serum HBV DNA was undetectable in 62.5% of the lymphoma patients at baseline. Patients were randomly assigned to either entecavir prophylaxis (started before chemotherapy until 3 mo after chemotherapy; n = 41) or therapeutic entecavir at the time of HBV reactivation (n = 39). The incidences of HBV reactivation at 18 mo of follow-up were 4.3% in the treatment group and 25.9% in the control group (P = 0.019). Although this study provided valuable information regarding preemptive antiviral therapy in lymphoma patients with “resolved” HBV infections, the study design seems debatable because 30 patients (37.5%) had “occult” HBV infections and were positive for serum HBV DNA. Those patients require preemptive antiviral therapy from the beginning of chemotherapy, rather than deferred treatment, according to the latest EASL guideline[62]. However, this study began in 2009, when there was no recommendation for a preemptive therapy in patients with occult/past infections. Thus, further studies with updated designs are warranted to support the findings of this trial.

Lastly, an interesting report from Singapore on the risk of HBV reactivation in patients with solid tumors was published recently. Ling et al[59] reported in their large-scale retrospective analysis (n = 1149) that only 0.3% (3 out of 1149) of patients developed HBV reactivation if they had not been screened for HBV infection prior to chemotherapy and instead received a doxorubicin-based regimen; on the other hand, those patients who received oxaliplatin/irinotecan-based or carboplatin plus gemcitabine capecitabine chemotherapy did not develop HBV reactivations. The authors argued that routine screening and preemptive therapy for lower-risk chemotherapy regimens may not be necessary, even in HBV-endemic regions.

**UNRESOLVED ISSUES AND FUTURE PERSPECTIVES**

**What is (are) the proper antiviral agent(s) for preemptive treatment?**

The current recommendations on the preemptive antiviral therapy are largely based on previous data from clinical trials of lamivudine in HBsAg-positive patients. Published studies, especially randomized trials, are mostly limited to lamivudine, both in lymphoma and in solid tumors[20,34,38,40]. A systematic review also concluded that preemptive lamivudine therapy reduced the risk of HBV reactivation-related hepatitis by approximately 80%[9]. However, the most concerning and serious drawback of lamivudine therapy is the emergence of resistant strains to lamivudine, as mentioned earlier[14]. In addition, the failure of prophylaxis with lamivudine due to virologic breakthroughs and cases of withdrawal hepatitis has been reported, especially if the baseline viral load was high or rituximab was used[41]. More potent antiviral agents with a high genetic barrier might be preferable, particularly in cases of high-risk patients for HBV reactivation or after prolonged chemotherapy. To date, however, only limited data exist on the prophylactic efficacy of such newer agents. A recent retrospective study from China reported the superiority of entecavir (n = 34) compared to lamivudine (n = 89) in preventing HBV reactivation in lymphoma patients[42]. Another multicenter retrospective study included a heterogeneous population with lymphoma and various solid tumors (n = 241), the results of which are currently available as an abstract; the results of that study showed that prophylaxis with entecavir (n = 31) or telbivudine (n = 124) was more effective than with lamivudine (n = 86). The HBV reactivation rate was not significantly different between entecavir and telbivudine[63]. A multicenter, randomized controlled trial comparing entecavir and lamivudine in patients with lymphoma or solid tumors is in progress, and the results are anticipated with keen interest (NCT01580202).

**What is the optimal duration of preemptive antiviral therapy?**

Discontinuation of lamivudine prophylaxis at 3 mo after the completion of chemotherapy resulted in an HBV reactivation rate of 24% in a previous study, especially among patients with high baseline HBV DNA levels[41]. The EASL guidelines strongly recommend continuing preemptive therapy for 12 mo in HBsAg-positive patients after the cessation of chemotherapy based on previous studies[9,14], with the level of evidence “A” and the grade of recommendation “1”[62]. However, neither of the two references for this recommendation provided sufficient evidence to support the preference of 12 mo of maintaining preemptive therapy over a shorter treatment duration. Furthermore, these references were based on studies using lamivudine[9,14], and currently, the data are insufficient to determine the optimal durations of more potent antiviral agents, such as entecavir or tenofovir. The AASLD guideline (2009) recommended a graded approach, in which lamivudine or telbivudine could be used for a planned duration of less than 12 mo, while entecavir or tenofovir was recommended for a longer duration of therapy[31]. However, supporting data were not sufficient for these recommendations. In addition, HBsAg titer is used for prediction of treatment response to peginterferon[60]. However, use of HBsAg quantification is currently not supported by sufficient evidence in terms of prediction of response or determination of duration of prophylactic antiviral therapy for HBV reactivation.

**Prophylaxis in patients with occult/past infections undergoing chemotherapy**

Based on the most recent reports described earlier, screening for evidence of past HBV infection in HBsAg-negative patients seems reasonable among high-risk patients, including those undergoing rituximab-based chemotherapy or with hematologic malignancies, especially in HBV-endemic areas. The randomized controlled trial of entecavir prophylaxis in patients with lymphoma and resolved HBV infections conveyed important messages.
for the management of patients at potential risk of HBV reactivation in the rituximab era. However, its study design, which included the possibility of assigning patients with occult infections with detectable serum HBV DNA to the control (or deferred treatment) arm, made it its conclusion somewhat questionable, as discussed earlier. Further compelling evidence is urgently required to resolve this unmet need.

CONCLUSION

Patients with HBV infections who receive anticancer chemotherapy are at risk of HBV reactivation during and after the completion of chemotherapy. Recent guidelines recommend preemptive antiviral therapy for HBsAg-positive patients undergoing chemotherapy, irrespective of their baseline viral load. However, the proper choice of antiviral agent and the optimal treatment duration are still under debate. Recently, several studies have reported the risk of reactivation in occult/past HBV infections. Based on the aforementioned observational studies and cost-effectiveness analyses, screening for occult/past infections in HBsAg-negative patients is strongly recommended, especially among lymphoma patients who receive rituximab-based chemotherapy or patients undergoing intensive immunosuppression. Again, the proper antiviral agent(s) and the optimal treatment duration remain unclear. Randomized controlled trials to compare different antiviral agents in homogeneous populations are urgently warranted to establish management strategies for the prevention of HBV reactivation in at-risk patients undergoing chemotherapy.

REFERENCES

1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. *Hepatology* 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/hep.23190]
2. Dienstag JL. Hepatitis B virus infection. *N Engl J Med* 2008; 359: 1486-1500 [PMID: 18832247 DOI: 10.1056/NEJM200808080300164]
3. Gupta S, Govindarajan S, Fong TL, Redeker AG. Spontaneous reactivation in chronic hepatitis B: patterns and natural history. *J Clin Gastroenterol* 1990; 12: 562-568 [PMID: 2230000]
4. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. *Hepatology* 2004; 39: 857-861 [PMID: 14999707 DOI: 10.1002/hep.20110]
5. Yeow W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. *Hepatology* 2006; 43: 209-220 [PMID: 16440366 DOI: 10.1002/hep.20515]
6. Yeow W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ. Comprehensive analysis of risk factors associated with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. *Br J Cancer* 2004; 90: 1306-1311 [PMID: 15054446 DOI: 10.1038/sj.bjc.6601699]
7. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. *Gastroenterology* 1991; 100: 182-188 [PMID: 1993820]
8. Yeow W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. *J Med Virol* 2000; 62: 299-307 [PMID: 11055299 DOI: 10.1002/1096-9071(200111)62:1<299::AID-JMV10>3.0.CO;2-3]
9. Loomba R, Rowley A, Wesley R, Liang T, Hoofnagle JH, Pucino F, Casco A. Systematic review: the effect of prophylactic lamivudine on hepatitis B reactivation during chemotherapy. *Ann Intern Med* 2008; 148: 519-528 [PMID: 18378948]
10. Kwak LW, Halpern J, Olshen RA, Hornig SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. *J Clin Oncol* 1990; 8: 963-977 [PMID: 2548230]
11. Bonadonna G, Valagussa P, Molinetti A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. *N Engl J Med* 1995; 332: 901-906 [PMID: 7877646 DOI: 10.1056/NEJM199504063321401]
12. Yeow W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. *J Med Virol* 2003; 70: 553-561 [PMID: 12794717 DOI: 10.1002/jmv.10430]
13. Takai S, Tsumori H, Ando K, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Takahashi T, Oyama M, Onishi H, Tomita E, Takami T, Imawari M, Moriwaki H. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. *Eur J Haematol* 2005; 74: 158-165 [PMID: 15659408]
14. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheang AL, Chen PT, A rev TY, Liu TW, Cheang AL, Chen PT. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. *Hepatology* 2008; 47: 844-853 [PMID: 18302290 DOI: 10.1002/hep.22106]
15. Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. *Lancet Oncol* 2010; 11: 827-834 [PMID: 20688564]
16. Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsai CJ, Kao WY, Uen WC, Hsu CH, Tien HF, Chao TY, Chen LT, Whang-Peng J. Steroid-free chemotherapy decreases risk of hepatitis B (HBV) reactivation in HBV-carriers with lymphoma. *Hepatology* 2003; 37: 1320-1328 [PMID: 12774010 DOI: 10.1038/jhep.2003.256 DOI: 10.1002/hep.20294]
17. Yeow W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. *J Clin Oncol* 2009; 27: 605-611 [PMID: 19075267 DOI: 10.1200/JCO.2008.18.0182]
18. Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, Hou JL, Wen YM, Nann J, Liang R. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in HBV-carriers with lymphoma. *Blood* 2002; 99: 2324-2330 [PMID: 11895763]
19. Lau GK, He ML, Fong DY, Bartholomewosz A, Au WY, Lie AK, Locarnini S, Liang R. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. *Hepatology* 2002; 36: 702-709 [PMID: 12198664]
20. Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. *Liver Int* 2004; 24: 540-546 [PMID: 15565002]
21. Kim MK, Ahn JH, Kim SB, Im YS, Lee SI, Ahn SH, Son BH, Gong G, Kim HH, Kim WK, Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution’s experience. *Korean J Intern Med* 2007; 22: 237-243 [PMID: 18309681]
Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwok YL, Liang R, Lau GK. Kinetics of risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherap-
y. Cancer Epidemiol Biomarkers Prev 2006; 15: 59-68 [PMID: 16831900]

El-Sayed MH, Mohamed MM, Karim A, Maina AM, Oliveri F, Brunetto MR, Bonino F. Severe liver disease is caused by
HBV rather than HCV in children with hematological ma-
nignancies. Hematol J 2003; 4: 321-327 [PMID: 14502256 DOI: 10.1088/sij/6200300]

Yeow W, Chan PK, Ho WM, Zee B, Lam KC, Lei KL, Chan AT, Mok TS, Lee J, Leung TW, Zhong S, Johnson Pj. Lamivu-
dine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing
cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-934 [PMID: 14990649 DOI:10.1200/JCO.2004.05.161

Yeow W, Zhong S, Chan PK, Ho WM, Wong HT, Chan AS, Johnson Pj. Sequence variations of precore/core and precore
promoter regions of hepatitis B virus in patients with or
without viral reactivation during cytotoxic chemotherapy. J
Viral Hepat 2000; 7: 448-458 [PMID: 11115057]

Nitsu N, Hagisawa Y, Tanaka K, Kohri M, Takahashi N. Prospective analysis of hepatitis B virus reactivation in patients with
diffuse large b-cell lymphoma after rituximab combina-
tion chemotherapy. J Clin Oncol 2010; 28: 5097-5100 [PMID:
20837949]

Tanaka Y, Esumi M, Shikata T. Persistence of hepatitis B vi-
rus DNA after serological clearance of hepatitis B virus. Liver
1990; 10: 6-10 [PMID: 2308481]

Koo Yy, Tan DS, Tan B, Tao M, Chow WC, Lim ST, Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving
chemoinmunotherapy. Cancer 2010; 116: 115-121 [PMID:
19899164 DOI:10.1002/cnr.24742]

Matsue K, Kimura S, Takeshita Y, Iwama K, Fujiwara H, Yamakura M, Takeuchi M. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-
positive b-cell lymphoma. Cancer 2010; 116: 4769-476 [PMID:
20357091 DOI:10.1002/cnr.25253]

Koo Yy, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST. Risk of hepatitis B virus (HBV)
reactivation in hepatitis B surface antigen negative/hepa-
titis B core antibody positive patients receiving rituximab-
containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 2011; 90: 1219-1223 [PMID:
21520016 DOI:10.1007/s00277-011-1344-0]

Viğano M, Vener C, Lampertico P, Annaloro C, Pichoud C, Zoulim F, Facchetti F, Poli F, Scalamagna M, Delliliers GL, Colombo M. Risk of hepatitis B surface antigen reversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 
46: 125-131 [PMID: 2083209 DOI:10.1038/bmt.2010.70]

Ceneli O, Ozkurt ZN, Akar C, Rota S, Aki SZ, Yeğin ZA, Yağcı M, Ozenerli S, Sucak GT. Hepatitis B-related events in
autologous hematopoietic stem cell transplantation re-
cipients. World J Gastroenterol 2010; 16: 1765-1771 [PMID:
20380100 DOI:10.3748/wjg.v16.i14.1765]

Borentain P, Colson P, Coso D, Bories E, Charbonnier A, Stoppa AM, Auran T, Loundou A, Mottet A, Ressiot E, Norquet E, Chabannon C, Bouabdallah R, Tamalet C, Gerolami R. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-
HBc antibodies-positive patients undergoing chemotherapy
and/or autologous stem cell transplantation for cancer. J
Viral Hepat 2010; 17: 807-815 [PMID: 2000298 DOI: 10.1111/j.
1365-2893.2009.01239.x]

Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following al-
logeneic hematopoietic stem cell transplantation. Blood Marrow Transplant 2009; 15: 1049-1059 [PMID: 19660717 DOI: 10.1016/j.bmt.2009.05.001]

Ji D, Cao J, Hong X, Li J, Wang J, Chen F, Wang C, Zou S. Low incidence of hepatitis B virus reactivation during che-
motherapy among diffuse large b-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study. Br J Haematol 2010; 85: 243-250 [PMID:
20491885 DOI:10.1111/j.1600-0609.2010.01474.x]

Ferreira R, Carvalheiro J, Torres J, Fernandes A, Giastas S, Mendes S, Agostinho C, Campos MJ. Fatal hepatitis B reac-
tivation treated with entecavir in an isolated anti-HBs posi-
tive lymphoma patient: a case report and literature review. Saud J Gastroenterol 2012; 18: 277-281 [PMID: 22624772 DOI: 10.4103/1319-3767.98436]

Rossi G, Pelizari A, Motta M, Puoti M. Primary prophyl-
axis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115: 58-62 [PMID:
11722410]

Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheng M, Zhang HY, Lie A, Ngan R, Liang R. Early is su-
uperior to deferred preemptive lamivudine therapy for hepa-
titis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749 [PMID: 14724827]

Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophyl-
axis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology 2007; 46: 1049-1056 [PMID:
17680560 DOI:10.1002/hep.21785]

European Association For The Study Of The Liver, EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012, 57: 167-185 [PMID: 22436845 DOI:10.1016/j.jhep.2012.02.010]

Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH, Wong BC, Leung N, Kwong YL, Liang R, Lau GK. Hepa-
titis B reactivation after withdrawal of pre-emptive lamivu-
dine in patients with haematological malignancy on comple-
tion of cytotoxic chemotherapy. Gut 2005; 54: 1597-1603 [PMID:
16000641]

Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, Zhai LZ, Pu XX, Huang Y, Guo CC, Lin TY. Comparison of ent-
ecavir and lamivudine in preventing hepatitis B reactiva-
tion in lymphoma patients during chemotherapy. J Viral Hepat 2011; 18: 877-883 [PMID: 21054683 DOI:10.1111/j.
1365-2893.2010.01386.x]

Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu Cj, Gane E, Locarnini S, Lim SC, Han KH. Asian-Pacific con-
sensus statement on the management of chronic hepatitis B. Int J Hepatol 2012. 6: 531-561

Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, Chen CH. Analysis of hepatitis B surface antibody titers in b-cell lymphoma patients after rituximab therapy. Ann Hematol 2012; 91: 1007-1012 [PMID: 22273839 DOI:10.1007/
s00277-012-1405-6]

Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, Kao WW, Chiu CF, Lin SF, Lin J, Chang CS, Tien HF, Liu TW, Chen PJ, Cheng AL. Chemotherapy-induced hepatitis B reac-
tivation in lymphoma patients with resolved HBV infection. Ann Hematol 2012; 91: 1007-1012 [PMID: 22273839 DOI:10.1007/
s00277-012-1405-6]

Matsui T, Kang JH, Nojima M, Tomonari A, Aoki H, Yamazaki H, Yane K, Tsuji K, Andoh S, Andoh S, Sakai K, Maemori M, Maguchi H, Tanaka Y. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple my-
eloma. J Med Virol 2013; 85: 1900-1906 [PMID: 23926682 DOI: 10.1002/jmv.23694]

Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan
Kim HY et al. Chemotherapy and HBV reactivation

KK, Feld JJ. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 2012; 30: 3167-3173 [PMID: 22718851 DOI: 10.1200/JCO.2011.40.7510]

Day FL, Karnon J, Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 2011; 29: 3270-3277 [PMID: 21788556 DOI: 10.1200/JCO.2011.55.1635]

Law JK, Ali JA, Harrigan PR, Sherlock CH, Savage KJ, Yoshida EM. Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol 2006; 81: 969-972 [PMID: 16937992 DOI: 10.1002/ajh.20737]

Schnepl N, Sellier P, Bendenoun M, Zini JM, Sanson-le Pors MJ, Mazeron MC. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. J Clin Virol 2007; 39: 48-50 [PMID: 17368969 DOI: 10.1016/j.jcv.2007.01.011]

Marino D, Boso C, Crivellati G, Mazzarotto R, Stragliotto S, Farinati F, Aversa SM. Fatal HBV-related liver failure during lamivudine therapy in a patient with non-Hodgkin’s lymphoma. Tumori 2008; 94: 745-748 [PMID: 19112953]

Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchi T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer 2013; 49: 3486-3496 [PMID: 23901049 DOI: 10.1016/j.ejca.2013.07.006]

Chen XQ, Peng JW, Lin GN, Li M, Xia ZJ. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBV-sAg-positive patients with diffuse large B cell lymphoma undergoing prolonged rituximab therapy. Med Oncol 2012; 29: 1257-1261 [PMID: 21556931 DOI: 10.1007/s12032-011-9974-0]

Rago A, Ridallo L, Lichtner M, Mecarocci S, Marrocro R, Centra N, Belvisi V, Mastroianni CM, Cimino G. Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine. J Antimicrob Chemother 2012; 67: 510-511 [PMID: 22110085 DOI: 10.1093/jac/dkr486]

Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, Cimino G, Vullo V. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011; 17: 3881-3887 [PMID: 22025876 DOI: 10.3748/wjg.v17.i34.3881]

Rago A, Lichtner M, Mecarocci S, Marrocro R, Centra N, Belvisi V, Del Borgo C, Cimino G, Mastroianni CM. Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen. Antivir Ther 2010; 15: 929-932 [PMID: 20834107 DOI: 10.3851/IPM1633]

Huang YH, Hsiao LT, Hong YC, Chiuo TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tseng CH, Lee PC, Lin HC, Lee SD. Randomized controlled trial of entecavir prophylaxis for ritximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-2772 [PMID: 2377967 DOI: 10.1200/JCO.2012.48.5938]

Ling WH, Soe PP, Pang AS, Lee SC. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer 2013; 108: 1931-1935 [PMID: 23652302 DOI: 10.1038/bjc.2013.225]

Long M, Jia W, Li S, Jin L, Wu J, Rao N, Feng H, Chen K, Deng H, Liu F, Su F, Song E. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat 2011; 127: 715-712 [PMID: 21445574 DOI: 10.1007/s10549-011-1455-9]

Kim IK, Kim BG, Kim W, Kim D, Kim YJ, Yoon JH, Lee HS. Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother 2012; 56: 5511-5519 [PMID: 22890764 DOI: 10.1128/AAC.00821-12]

Yoo J, Kim HY, Lee JH, Yu SJ, Kim YJ, Yoon JH, Lee HS. Comparison of Lamivudine, Telbivudine, and Entecavir as Antiviral Prophylaxis for Patients with Hepatitis B Undergoing Cytotoxic Chemotherapy. Proceedings of the HEPATOL-LOGY; Hoboken, NJ: Wiley-Blackwell, 2012: 631A-631A

Zhong S, Yang Y, Yang Y, Zhang J, Zou J, Zhang X, Wu J, Wang H, Li Y, Zhang Z, Wang M, Li X. Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Anticancer Res 2012; 32: 421-426 [PMID: 21551005 DOI: 10.1093/annonc/mdr142]

Chen XQ, Peng JW, Lin GN, Li M, Xia ZJ. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBV-sAg-positive patients with diffuse large B cell lymphoma undergoing prolonged rituximab therapy. Med Oncol 2012; 29: 1257-1261 [PMID: 21556931 DOI: 10.1007/s12032-011-9974-0]

Rago A, Ridallo L, Lichtner M, Mecarocci S, Marrocro R, Centra N, Belvisi V, Mastroianni CM, Cimino G. Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine. J Antimicrob Chemother 2012; 67: 510-511 [PMID: 22110085 DOI: 10.1093/jac/dkr486]

Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, Cimino G, Vullo V. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011; 17: 3881-3887 [PMID: 22025876 DOI: 10.3748/wjg.v17.i34.3881]

Rago A, Lichtner M, Mecarocci S, Marrocro R, Centra N, Belvisi V, Del Borgo C, Cimino G, Mastroianni CM. Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen. Antivir Ther 2010; 15: 929-932 [PMID: 20834107 DOI: 10.3851/IPM1633]

Huang YH, Hsiao LT, Hong YC, Chiuo TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tseng CH, Lee PC, Lin HC, Lee SD. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-2772 [PMID: 2377967 DOI: 10.1200/JCO.2012.48.5938]
